Selçuk Ecza Valuation Multiples

Discover revenue and EBITDA valuation multiples for Selçuk Ecza and similar public comparables like Yifeng Pharmacy, Jointown Pharmaceutical, CR Pharmaceutical, Nahdi Medical and more.

Selçuk Ecza Overview

About Selçuk Ecza

Selcuk Ecza Deposu Ticaret ve Sanayi AS and its subsidiaries are in the business of export and import of drugs and patent medicines, medical supplies with pharmacy depot operations and also organize distribution channels between drug manufacturers, hospitals, and pharmacies. The company also distributes cosmetics, personal care, infant food, vitamins, medical and similar products.


Founded

1970

HQ

Turkey

Employees

6.5K

Sectors

Financials (LTM)

Revenue: $4.5B
EBITDA: $115M

EV

$4.3B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Selçuk Ecza Financials

Selçuk Ecza reported last 12-month revenue of $4.5B and EBITDA of $115M.

In the same LTM period, Selçuk Ecza generated $115M in EBITDA and had net loss of ($10M).

Revenue (LTM)


Selçuk Ecza P&L

In the most recent fiscal year, Selçuk Ecza reported revenue of $3.6B and EBITDA of $41M.

Selçuk Ecza is unprofitable as of last fiscal year, with gross margin of 8%, EBITDA margin of 1%, and net margin of (0%).

See analyst estimates for Selçuk Ecza
LTMLast FY202320242025202620272028
Revenue$4.5B$3.6B$2B$2.7B$3.6B
Gross Profit-$294M$191M$272M$294M
Gross Margin-8%9%10%8%
EBITDA$115M$41M$48M$131M$41M
EBITDA Margin3%1%2%5%1%
EBIT Margin2%2%5%4%2%
Net Profit($10M)($8M)$5M$43M($8M)
Net Margin(0%)(0%)0%2%(0%)
Net Debt-($7M)---

Financial data powered by Morningstar, Inc.

Selçuk Ecza Stock Performance

Selçuk Ecza has current market cap of $4.4B, and enterprise value of $4.3B.

Market Cap Evolution


Selçuk Ecza's stock price is $7.16.

Selçuk Ecza share price increased by 3.5% in the last 30 days, and by 272.5% in the last year.

Selçuk Ecza has an EPS (earnings per share) of $-0.01.

See more trading valuation data for Selçuk Ecza
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$4.3B$4.4B2.2%3.5%59.3%272.5%$-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Selçuk Ecza Valuation Multiples

Selçuk Ecza trades at 1.0x EV/Revenue multiple, and 37.5x EV/EBITDA.

See NTM and 2027E valuation multiples for Selçuk Ecza

EV / Revenue (LTM)


Selçuk Ecza Financial Valuation Multiples

As of September 4, 2026, Selçuk Ecza has market cap of $4.4B and EV of $4.3B.

Selçuk Ecza has a P/E ratio of (447.3x).

LTMLast FY202320242025202620272028
EV/Revenue1.0x1.2x2.1x1.6x1.2x
EV/EBITDA37.5x104.4x89.5x33.1x104.4x
EV/EBIT41.7x55.5x44.6x38.5x55.5x
EV/Gross Profit-14.7x22.6x15.9x14.7x
P/En/mn/mn/m103.4xn/m
EV/FCF17.6x32.8x175.9x(22.2x)32.8x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Selçuk Ecza Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Selçuk Ecza Margins & Growth Rates

Selçuk Ecza grew revenue by 47% and EBITDA by 485% in the last fiscal year.

In the most recent fiscal year, Selçuk Ecza reported gross margin of 8%, EBITDA margin of 1%, and net margin of (0%).

See estimated margins and future growth rates for Selçuk Ecza

Selçuk Ecza Margins

Last FY202420252026202720282029
Gross Margin8%10%8%-
EBITDA Margin1%5%1%5%
EBIT Margin2%4%2%5%
Net Margin(0%)2%(0%)2%
FCF Margin4%(7%)4%2%

Selçuk Ecza Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth47%32%33%47%
Gross Profit Growth-42%8%-
EBITDA Growth485%170%(68%)485%
EBIT Growth206%16%(31%)206%
Net Profit Growth(1418%)822%(118%)(1418%)
FCF Growth(16%)(893%)(168%)(16%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Selçuk Ecza Operational KPIs

Selçuk Ecza's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.0M for the same period.

Selçuk Ecza's Rule of 40 is 52% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Selçuk Ecza's Rule of X is 122% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Selçuk Ecza
LTMLast FY202320242025202620272028
Rule of 4032%52%---
Bessemer Rule of X77%122%---
Revenue per Employee-$0.6M---
Opex per Employee-$0.0M---
S&M Expenses to Revenue-0%4%5%0%
G&A Expenses to Revenue-1%1%1%1%
Opex to Revenue-6%5%6%6%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Selçuk Ecza Competitors

Selçuk Ecza competitors include Yifeng Pharmacy, Jointown Pharmaceutical, CR Pharmaceutical, Nahdi Medical, COSMOS Pharmaceutical, DaShenLin Pharmaceutical, Sugi Holdings, Clicks Group, Alibaba Health and Tsuruha Holdings.

Most Selçuk Ecza public comparables operate across Pharmacies.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Yifeng Pharmacy1.0x0.9x5.4x5.5x
Jointown Pharmaceutical0.2x0.2x6.3x6.8x
CR Pharmaceutical0.5x0.5x7.4x7.6x
Nahdi Medical1.2x1.2x7.5x7.2x
COSMOS Pharmaceutical0.5x0.5x7.6x7.8x
DaShenLin Pharmaceutical0.8x0.7x6.2x6.3x
Sugi Holdings0.4x0.4x6.9x6.1x
Clicks Group1.1x1.0x7.8x7.5x

This data is available for Pro users. Sign up to see all Selçuk Ecza competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Selçuk Ecza

When was Selçuk Ecza founded?Selçuk Ecza was founded in 1970.
Where is Selçuk Ecza headquartered?Selçuk Ecza is headquartered in Turkey.
How many employees does Selçuk Ecza have?As of today, Selçuk Ecza has over 6K employees.
Is Selçuk Ecza publicly listed?Yes, Selçuk Ecza is a public company listed on Borsa Istanbul.
What is the stock symbol of Selçuk Ecza?Selçuk Ecza trades under SELEC ticker.
When did Selçuk Ecza go public?Selçuk Ecza went public in 2006.
Who are competitors of Selçuk Ecza?Selçuk Ecza main competitors include Yifeng Pharmacy, Jointown Pharmaceutical, CR Pharmaceutical, Nahdi Medical, COSMOS Pharmaceutical, DaShenLin Pharmaceutical, Sugi Holdings, Clicks Group, Alibaba Health, Tsuruha Holdings.
What is the current market cap of Selçuk Ecza?Selçuk Ecza's current market cap is $4.4B.
What is the current revenue of Selçuk Ecza?Selçuk Ecza's last 12 months revenue is $4.5B.
What is the current revenue growth of Selçuk Ecza?Selçuk Ecza revenue growth (NTM/LTM) is 30%.
What is the current EV/Revenue multiple of Selçuk Ecza?Current revenue multiple of Selçuk Ecza is 1.0x.
What is the current EBITDA of Selçuk Ecza?Selçuk Ecza's last 12 months EBITDA is $115M.
What is Selçuk Ecza's EBITDA margin?Selçuk Ecza's last 12 months EBITDA margin is 3%.
What is the current EV/EBITDA multiple of Selçuk Ecza?Current EBITDA multiple of Selçuk Ecza is 37.5x.
What is the current FCF of Selçuk Ecza?Selçuk Ecza's last 12 months FCF is $246M.
What is Selçuk Ecza's FCF margin?Selçuk Ecza's last 12 months FCF margin is 5%.
What is the current EV/FCF multiple of Selçuk Ecza?Current FCF multiple of Selçuk Ecza is 17.6x.
How many companies Selçuk Ecza has acquired to date?Selçuk Ecza hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Selçuk Ecza has invested to date?Selçuk Ecza hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Selçuk Ecza

Lists including Selçuk Ecza

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial